BioMarin Pharmaceutical Inc. filed its third-quarter 2026 financial results on November 2, 2026, reporting total revenues of $1.025 billion for the three months ended September 30, 2026, the first quarter in company history to exceed $1 billion in revenue.

Key Highlights

  • Total revenues of $1,025 million in Q3 2026, a 32% increase compared to the same period in 2025, according to the filing.
  • GAAP net loss of $123 million in Q3 2026, compared to a net loss of $31 million in Q3 2025, driven in part by intangible asset amortization, interest expense, and IPR&D charges related to the Amicus and Alesta acquisitions.
  • Non-GAAP income of $45 million in Q3 2026, up from $22 million in Q3 2025, a 105% increase.
  • Metabolic Conditions revenue grew 44% year-over-year to $744 million in Q3 2026, driven by the additions of GALAFOLD ($152 million) and POMBILITI + OPFOLDA ($49 million), acquired from Amicus on April 27, 2026.
  • VOXZOGO revenue increased 12% year-over-year to $245 million in Q3 2026, with the number of children treated globally rising 17% year-over-year across 58 countries.
  • FDA set a PDUFA target action date of May 30, 2027 for BioMarin's supplemental NDA to expand VOXZOGO use for the treatment of hypochondroplasia.
  • Full-year 2026 guidance was updated to reflect order timing uncertainty and the impact of two acquired IPR&D charges, the company disclosed.

BioMarin's Q3 2026 Revenue Growth and Amicus Integration Shape Financial Results

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reported third-quarter 2026 total revenues of $1,025 million, a 32% increase over the $776 million reported for the same period in 2025, according to the filing. The company attributed the growth primarily to revenues from GALAFOLD and POMBILITI + OPFOLDA, acquired from Amicus Therapeutics on April 27, 2026, as well as 18% revenue growth in VIMIZIM due to timing of large international orders. VOXZOGO revenue also increased 12%, driven by new patients initiating therapy, though a large international order expected in Q3 was said to be anticipated in Q4 instead.

On a GAAP basis, the company reported a net loss of $123 million in Q3 2026, compared to a net loss of $31 million in Q3 2025. The filing attributed the increase to the Amicus acquisition, including intangible asset amortization, interest expense from acquisition-related debt, amortization of inventory fair value step-up, integration and restructuring costs, and IPR&D charges related to the acquisition of Alesta Therapeutics. Non-GAAP income for the quarter was $45 million, up from $22 million in Q3 2025. GAAP diluted EPS was $(0.63) versus $(0.16) a year earlier, while Non-GAAP diluted EPS was $0.23 versus $0.12.

The filing noted that BioMarin continues to expect approximately $280 million of GAAP cost synergies (approximately $220 million on a Non-GAAP basis) from the Amicus integration to be fully realized in 2028. Four pipeline transactions in 2026 added programs from preclinical through Phase 3, including BMN 450, a potential subcutaneous enzyme replacement therapy for Fabry disease now in a global Phase 1/2 study. The company also disclosed that the FDA has set a PDUFA action date of February 28, 2027, for full approval of VOXZOGO in children with achondroplasia, and that the settlement with Ascendis Pharma entitles BioMarin to a 20% royalty on U.S. net sales of Yuviwel and an 18% royalty in the European Union, Brazil, and South Korea until May 2030.

What Was Disclosed

BioMarin disclosed Q3 2026 financial results including revenues of $1,025 million, a GAAP net loss of $123 million, Non-GAAP income of $45 million, pipeline updates across four new 2026 business development transactions, updated full-year 2026 guidance, and two new PDUFA action dates for VOXZOGO.